Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
The interaction of PD-1 with pembrolizumab Fab buries ∼1 774 Š2 surface area, and the hPD-1/Fab interface can be divided into two sub-interfaces. Sub-interface I mainly encompasses the C′D loop of ...
Immune checkpoints are regulators of the immune system. The interaction between PD-L1 (red molecule) on the surface of a cancer cell (red) and the immune checkpoint PD-1 (blue molecule) on a T-cell ...
Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 blockade as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback